# Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer

## TL;DR

This study examines how stereotactic body radiation therapy (SBRT) affects treatment changes in patients with advanced breast cancer.

## Contribution

The study shows SBRT delays the need for new systemic treatments in oligometastatic breast cancer patients.

## Key findings

- SBRT delayed systemic treatment changes by over one year in the studied patient group.
- SBRT was found to be well-tolerated with minimal toxicity.
- Randomized trials are recommended to confirm SBRT's survival benefits.

## Abstract

•SBRT is widely used in oligometastatic breast cancer despite limited evidence.•SBRT delayed systemic therapeutic line change by over 1 year in our cohort.•Our study may help to identify patients most likely to benefit from SBRT.•SBRT is a well-tolerated treatment with limited toxicity.•Randomized trials are needed to assess the benefit of SBRT in terms of survival.

SBRT is widely used in oligometastatic breast cancer despite limited evidence.

SBRT delayed systemic therapeutic line change by over 1 year in our cohort.

Our study may help to identify patients most likely to benefit from SBRT.

SBRT is a well-tolerated treatment with limited toxicity.

Randomized trials are needed to assess the benefit of SBRT in terms of survival.